#Japan #Tokyo #Healthcare Innovation #BioPhenoMA #TN-cyclon

BioPhenoMA Announces Executive Leadership Change

BioPhenoMA Inc., founded in April 2023, is making waves in the life sciences sector with its cutting-edge protein detection technology. Aimed at contributing significantly to early disease diagnosis and preventive medicine, the company has recently announced a change in executive leadership that is set to steer its vision forward.

At the heart of BioPhenoMA’s mission is the innovative TN-cyclon™ technology, developed by Professor Etsurou Ito from Waseda University. This high-sensitivity detection method is designed to transform clinical testing and protein quantification, allowing for early detection and intervention in diseases, especially in fields with pressing societal needs, like cancer and neurodegenerative disorders.

In its commitment to advancing healthcare, BioPhenoMA will focus on developing groundbreaking in vitro diagnostics (IVDs) and companion diagnostics (CDx) in collaboration with pharmaceutical companies. These products are not just aimed at bringing advanced technology to the market but are also designed to serve as essential tools in therapeutic decision-making.

The company’s innovative approach positions it uniquely in the biotechnology landscape, particularly with the pressing challenges posed by infectious diseases. As the prevalence of tropical diseases grows worldwide, BioPhenoMA aspires to leverage its technology to contribute to global health efforts and the eradication of such threats.

Business Theme

BioPhenoMA emphasizes a clear business theme: “Quantifying and Connecting to Treatment for Pre-disease.” By defining the boundary between health and disease, BioPhenoMA focuses on quantifying and visualizing pre-disease states. This initiative is expected to drive early detection, timely treatment, and ultimately enhance preventive health measures. Through rigorous testing and innovative diagnostics, the company aims to contribute to building a healthier, more affluent society.

Insights from the New CEO, Masahiro Mitamura

With the recent leadership change, Masahiro Mitamura stepped into the role of Chief Executive Officer. He expressed, “I am honored to take on this position. For over 35 years, I have dedicated myself to various social initiatives, particularly in supporting cancer patients and their families. This includes efforts in building a robust healthcare infrastructure, reforming social systems, and establishing the Japan Marrow Bank. I will continue to advocate for the health of our communities through innovative medical solutions.”

His background includes extensive experience in research and development, marketing, and business development in both domestic and international medical device, genetic medicine, and diagnostics sectors, greatly enriching BioPhenoMA’s leadership.

Mitamura's prior roles include being the former board member of the Japan Marrow Bank and representing Asia in the Patient Advocacy Committee for the World Bone Marrow Transplantation Group (WBMT), under the auspices of WHO. He has been recognized as one of the top 100 global leaders in healthcare innovation by Health 2.0 in 2023, showcasing his influence and commitment to health advancement.

New Executive Team

The new executive lineup effective from June 30, 2025, features:

• - CEO: Masahiro Mitamura
• - Director: Etsurou Ito
• - Director: Daisuke Niwa

BioPhenoMA remains dedicated to its foundational mission, committed to delivering high-value diagnostics that enhance health outcomes. Operating from its headquarters in Shinjuku, Tokyo, the company is recalibrating its strategies to ensure impactful contributions to global health.

For further information, please visit BioPhenoMA's website or contact them at [email protected].